H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Xoma (XOMA – Research Report) today and set a price target of $69.00. The company’s shares closed last Thursday at $21.82.
According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -29.1% and a 21.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics.
Currently, the analyst consensus on Xoma is a Moderate Buy with an average price target of $69.00.
See today’s best-performing stocks on TipRanks >>
Xoma’s market cap is currently $249.3M and has a P/E ratio of 42.05.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Read More on XOMA:
- Christina Lake Cannabis Appoints Experienced Cannabis Executive Mark Aiken as CEO
- Correction of Press Release Announcing Amendments to NFI Group’s Credit Facilities
- Monness Downgrades Datadog (DDOG) to Hold
- Astar Network Partners with Alchemy to Stoke Web3 Development on Polkadot
- After Gaining 9% on Wednesday, PayPal Stock Could Go Up Another 37%, Says Analyst
